US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · COVID-19 · Poliomyelitis
Sinovac Research and
Sinovac Research and Development Co.,
Sinovac Research and drug portfolio — 54 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Dhaka, CN HQ
2022 Founded
9 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Dhaka, CN
- Founded
- 2022
- Employees
- 9
- Programs
- 115
- Drugs
- 54
- Patents
- 0
Sinovac Research and pipeline
Portfolio lens on 54 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Sinovac Research and drug portfolio — 54 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Dopamine receptors; D2 & D3.
- Target
- Dopamine receptors; D2 & D3
- Mechanism
- Serotonin (5-HT) receptor antagonist
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Sinovac Research and's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
dengue tetravalent vaccine (live, attenuated)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Sinovac Research and's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
diphtheria (d), tetanus (t), pertussis (acellular, component) (pa), hepatitis b (rdna) (hbv), poliomyelitis (inactivated) (ipv) and haemophilus influenzae type-b (hib) conjugate vaccine (adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Sinovac Research and's portfolio.
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
hepatitis a (inactivated) and hepatitis b (rdna) (hab) vaccine (adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Sinovac Research and's portfolio. Molecular target: Surface antigen (HBsAg).
- Target
- Surface antigen (HBsAg)
- Mechanism
- Surface antigen (HBsAg) vaccine antigen
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
human heterologous liver cells
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in Sinovac Research and's portfolio.
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
influenza vaccine (h1n1)v (split virion, inactivated, adjuvanted)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Sinovac Research and's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
influenza vaccine (h1n1)v (whole virion, vero cell derived, inactivated)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Sinovac Research and's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
influenza vaccine (live attenuated, nasal)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Sinovac Research and's portfolio.
-
influenza vaccine (split virion, inactivated)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Sinovac Research and's portfolio.
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
Development asset linked to Sinovac Research and in public FDA and regional records. Mechanism: Muscarinic acetylcholine receptor M3 antagonist.
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
measles, mumps and rubella vaccine (live)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Sinovac Research and's portfolio.
-
measles, mumps, rubella and varicella vaccine (live)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Sinovac Research and's portfolio.
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
pandemic influenza vaccine (h1n1) (split virion, inactivated, adjuvanted)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Sinovac Research and's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
quadrivalent influenza vaccine (recombinant, prepared in cell culture)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Sinovac Research and's portfolio.
-
Development asset linked to Sinovac Research and in public FDA and regional records. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
shingles (herpes zoster) vaccine (live)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Sinovac Research and's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
trivalent influenza vaccine (recombinant, prepared in cell culture)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Sinovac Research and's portfolio.
-
ulipristal acetate
Genito-urinary system and sex hormones (G03)US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor modulator
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
Development asset linked to Sinovac Research and in public FDA and regional records.
-
vimseltinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved.